1.Detection and clinical significance of NTRK in digestive system neoplasms.
X J HOU ; Y FU ; X H PU ; X S FAN
Chinese Journal of Pathology 2023;52(8):876-880
2.Microsatellite Instability of Gastric and Colorectal Cancers as a Predictor of Synchronous Gastric or Colorectal Neoplasms.
Young Beak KIM ; Sun Young LEE ; Jeong Hwan KIM ; In Kyung SUNG ; Hyung Seok PARK ; Chan Sup SHIM ; Hye Seung HAN
Gut and Liver 2016;10(2):220-227
BACKGROUND/AIMS: Microsatellite instability (MSI) plays a crucial role in gastrointestinal carcinogenesis. The aim of this study was to clarify whether MSI is a useful marker for predicting synchronous gastric and colorectal neoplasms. METHODS: Consecutive patients who underwent both esophagogastroduodenoscopy and colonoscopy before the resection of gastric or colorectal cancers were included. MSI was analyzed using two mononucleotide and three dinucleotide markers. RESULTS: In total, 434 gastric cancers (372 microsatellite stability [MSS], 21 low incidence of MSI [MSI-L], and 41 high incidence of MSI [MSI-H]) and 162 colorectal cancers (138 MSS, 9 MSI-L, and 15 MSI-H) were included. Patients with MSI gastric cancer had a higher prevalence of synchronous colorectal cancer, colorectal adenoma, and gastric adenoma than those with MSS gastric cancers (4.8% vs 0.5%, p=0.023; 11.3% vs 3.2%, p=0.011; 3.2% vs 1.2%, p=0.00, respectively). The prevalence of synchronous colorectal adenomas was highest in MSI-L gastric cancers (19.0%), compared with MSI-H (7.3%) or MSS (3.2%) gastric cancers (p=0.002). In addition, there were no significant differences in the prevalence rates of synchronous colorectal adenoma among the MSI-H (13.3%), MSI-L (11.1%), and MSS (12.3%) colorectal cancers (p=0.987). CONCLUSIONS: The presence of MSI in gastric cancer may be a predictor of synchronous gastric and colorectal neoplasms, whereas MSI in colorectal cancer is not a predictor of synchronous colorectal adenoma.
Adenoma/*genetics/surgery
;
Aged
;
Colonoscopy
;
Colorectal Neoplasms/*genetics/surgery
;
Endoscopy, Digestive System
;
Female
;
Humans
;
Male
;
*Microsatellite Instability
;
Middle Aged
;
Neoplasms, Multiple Primary/*genetics/surgery
;
Predictive Value of Tests
;
Stomach Neoplasms/*genetics/surgery
3.Comorbid Gastric Adenocarcinoma and Gastric and Duodenal Strongyloides stercoralis Infection: A Case Report.
An Na SEO ; Youn Kyoung GOO ; Dong Il CHUNG ; Yeonchul HONG ; Ohkyoung KWON ; Han Ik BAE
The Korean Journal of Parasitology 2015;53(1):95-99
Strongyloides stercoralis can cause systemic infection, termed strongyloidiasis, and gastrointestinal ulcer disease in immunocompromised patients. However, to our knowledge, there are no reported cases of comorbid gastric adenocarcinoma and S. stercoralis infection. Here, we report a case of an 81-year-old Korean man who presented with S. stercoralis infection coexisting with early gastric adenocarcinoma (T1aN0M0). S. stercoralis eggs, rhabditiform larvae, and adult females were observed in normal gastric and duodenal crypts. They were also observed in atypical glands representative of adenocarcinoma and adenoma. Preliminary laboratory tests revealed mild neutrophilic and eosinophilic leukocytosis. A routine stool test failed to detect rhabditiform larvae in the patient's fecal sample; however, S. stercoralis was identified by PCR amplification and 18S rRNA sequencing using genomic DNA extracted from formalin-fixed paraffin-embedded tissues. Postoperatively, the patient had a persistent fever and was treated with albendazole for 7 days, which alleviated the fever. The patient was followed-up by monitoring and laboratory testing for 4 months postoperatively, and no abnormalities were observed thus far. The fact that S. stercoralis infection may be fatal in immunocompromised patients should be kept in mind when assessing high-risk patients.
Adenocarcinoma/*complications/*diagnosis/pathology
;
Aged, 80 and over
;
Albendazole/therapeutic use
;
Animals
;
Anthelmintics/therapeutic use
;
DNA, Helminth/chemistry/genetics
;
DNA, Ribosomal/chemistry/genetics
;
Endoscopy, Digestive System
;
Female
;
Histocytochemistry
;
Humans
;
Korea
;
Male
;
RNA, Ribosomal, 18S/genetics
;
Sequence Analysis, DNA
;
Stomach Neoplasms/*complications/*diagnosis/pathology
;
Strongyloides stercoralis/*isolation & purification
;
Strongyloidiasis/*complications/*diagnosis/drug therapy/pathology
;
Treatment Outcome
4.Comorbid Gastric Adenocarcinoma and Gastric and Duodenal Strongyloides stercoralis Infection: A Case Report.
An Na SEO ; Youn Kyoung GOO ; Dong Il CHUNG ; Yeonchul HONG ; Ohkyoung KWON ; Han Ik BAE
The Korean Journal of Parasitology 2015;53(1):95-99
Strongyloides stercoralis can cause systemic infection, termed strongyloidiasis, and gastrointestinal ulcer disease in immunocompromised patients. However, to our knowledge, there are no reported cases of comorbid gastric adenocarcinoma and S. stercoralis infection. Here, we report a case of an 81-year-old Korean man who presented with S. stercoralis infection coexisting with early gastric adenocarcinoma (T1aN0M0). S. stercoralis eggs, rhabditiform larvae, and adult females were observed in normal gastric and duodenal crypts. They were also observed in atypical glands representative of adenocarcinoma and adenoma. Preliminary laboratory tests revealed mild neutrophilic and eosinophilic leukocytosis. A routine stool test failed to detect rhabditiform larvae in the patient's fecal sample; however, S. stercoralis was identified by PCR amplification and 18S rRNA sequencing using genomic DNA extracted from formalin-fixed paraffin-embedded tissues. Postoperatively, the patient had a persistent fever and was treated with albendazole for 7 days, which alleviated the fever. The patient was followed-up by monitoring and laboratory testing for 4 months postoperatively, and no abnormalities were observed thus far. The fact that S. stercoralis infection may be fatal in immunocompromised patients should be kept in mind when assessing high-risk patients.
Adenocarcinoma/*complications/*diagnosis/pathology
;
Aged, 80 and over
;
Albendazole/therapeutic use
;
Animals
;
Anthelmintics/therapeutic use
;
DNA, Helminth/chemistry/genetics
;
DNA, Ribosomal/chemistry/genetics
;
Endoscopy, Digestive System
;
Female
;
Histocytochemistry
;
Humans
;
Korea
;
Male
;
RNA, Ribosomal, 18S/genetics
;
Sequence Analysis, DNA
;
Stomach Neoplasms/*complications/*diagnosis/pathology
;
Strongyloides stercoralis/*isolation & purification
;
Strongyloidiasis/*complications/*diagnosis/drug therapy/pathology
;
Treatment Outcome
5.Role of TROP2 in cancer and as potential therapeutic target.
Chinese Journal of Pathology 2013;42(12):860-863
Animals
;
Antigens, Neoplasm
;
genetics
;
metabolism
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Brain Neoplasms
;
metabolism
;
Cell Adhesion Molecules
;
genetics
;
metabolism
;
Digestive System Neoplasms
;
metabolism
;
Female
;
Genital Neoplasms, Female
;
metabolism
;
Glioma
;
metabolism
;
Head and Neck Neoplasms
;
metabolism
;
Humans
;
Immunotherapy
;
Male
;
Prostatic Neoplasms
;
metabolism
;
Signal Transduction
6.Nrf2 as a chemoprevention target in gastrointestinal carcinoma.
Peng GAO ; Xiu-wen TANG ; Xiu-jun WANG
Journal of Zhejiang University. Medical sciences 2012;41(4):453-463
Gastrointestinal tract carcinoma is one of the leading causes of cancer-related death in China. Chemoprevention has been considered as a potential approach to control this type of disease. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor that protects cells from oxidative/electrophilic stresses by activating the expression of a battery of cytoprotective genes through the antioxidant response element (ARE). Recently, Nrf2 has emerged as a novel target for chemoprevention. Several natural or synthetic chemicals, which activate Nrf2/ARE signaling pathway, have showed effect in animal models, and promises in many ongoing clinical trials. This review summarizes the recent findings on the regulation of Nrf2/ARE signaling pathway, and the developments in both preclinical and clinical studies.
Animals
;
Anticarcinogenic Agents
;
pharmacology
;
Antioxidants
;
metabolism
;
Chemoprevention
;
Digestive System Neoplasms
;
genetics
;
metabolism
;
prevention & control
;
Humans
;
NF-E2-Related Factor 2
;
genetics
;
metabolism
;
Oxidative Stress
;
drug effects
;
Response Elements
;
genetics
;
Signal Transduction
;
drug effects
7.Recent advances on EZH2 in malignant tumors.
Chinese Journal of Pathology 2009;38(12):856-858
Biomarkers, Tumor
;
metabolism
;
Breast Neoplasms
;
metabolism
;
DNA-Binding Proteins
;
genetics
;
metabolism
;
Digestive System Neoplasms
;
metabolism
;
Enhancer of Zeste Homolog 2 Protein
;
Female
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Lymphoma
;
metabolism
;
Polycomb Repressive Complex 2
;
Prognosis
;
RNA, Messenger
;
metabolism
;
Transcription Factors
;
genetics
;
metabolism
;
Urogenital Neoplasms
;
metabolism
8.Evaluation of the criterion of partial loss of heterozygous in tumor tissues.
Cheng-Tao LI ; Shu-Min ZHAO ; Su-Hua ZHANG ; Li LI
Journal of Forensic Medicine 2009;25(6):417-420
OBJECTIVE:
To evaluate the applicability of partial loss of heterozygous (pLOH) criteria in tumor tissues with Identifiler system.
METHODS:
Eight thousand four hundred and twenty eight heterozygous loci of the 696 unrelated individuals (UIP) genotyped with Identifiler Kit were randomly paired by locus to construct odds ratio of allelic peak height (or area under allelic curve) according to the given formula. Similarly, odds ratios of allelic peak height (or area under allelic curve) of the 896 heterozygous loci of 77 pairs of tumor and homologous normal tissues (TNP) were also acquired. Curve fitting was performed to determine the distribution of the odds ratio. The proportion of pLOH in two groups was determined with odds ratio less than 0.5 or higher than 2.0. Compared the relevance ratio of allelic peak height and peak area by chi2 test.
RESULTS:
The odds ratio of both peak height and peak area presented normal distribution in UIP (4214 heterozygous loci pairs) and TNP group (896 heterozygous loci pairs). There was 0.12% of normal heterozygous in UIP group erroneously presumed as pLOH with current criteria (< 0.5 or > 2.0). There was no significantly difference between the calling rate based on two types of odd ratio (P = -0.5632).
CONCLUSION
It is feasible to determine the pLOH in tumor tissue with Identifiler system by both peak height and peak area according to the standards of the odds ratio less than 0.5 or higher than 2.0.
Alleles
;
Digestive System Neoplasms/genetics*
;
Female
;
Gene Frequency
;
Humans
;
Loss of Heterozygosity
;
Male
;
Mutation
;
Odds Ratio
;
Polymerase Chain Reaction/methods*
;
Tandem Repeat Sequences/genetics*
9.Phenotypic heterogeneity of mutations in androgen receptor gene.
Singh RAJENDER ; Lalji SINGH ; Kumarasamy THANGARAJ
Asian Journal of Andrology 2007;9(2):147-179
Androgen receptor (AR) gene has been extensively studied in diverse clinical conditions. In addition to the point mutations, trinucleotide repeat (CAG and GGN) length polymorphisms have been an additional subject of interest and controversy among geneticists. The polymorphic variations in triplet repeats have been associated with a number of disorders, but at the same time contradictory findings have also been reported. Further, studies on the same disorder in different populations have generated different results. Therefore, combined analysis or review of the published studies has been of much value to extract information on the significance of variations in the gene in various clinical conditions. AR genetics has been reviewed extensively but until now review articles have focused on individual clinical categories such as androgen insensitivity, male infertility, prostate cancer, and so on. We have made the first effort to review most the aspects of AR genetics. The impact of androgens in various disorders and polymorphic variations in the AR gene is the main focus of this review. Additionally, the correlations observed in various studies have been discussed in the light of in vitro evidences available for the effect of AR gene variations on the action of androgens.
Androgen-Insensitivity Syndrome
;
genetics
;
physiopathology
;
Bone Diseases, Metabolic
;
genetics
;
physiopathology
;
Breast Neoplasms
;
genetics
;
physiopathology
;
Cognition Disorders
;
genetics
;
physiopathology
;
Digestive System Diseases
;
genetics
;
physiopathology
;
Female
;
Genital Neoplasms, Female
;
genetics
;
physiopathology
;
Genital Neoplasms, Male
;
genetics
;
physiopathology
;
Humans
;
Infertility, Male
;
genetics
;
Male
;
Muscular Atrophy, Spinal
;
genetics
;
physiopathology
;
Phenotype
;
Point Mutation
;
Polycystic Ovary Syndrome
;
genetics
;
physiopathology
;
Polymorphism, Genetic
;
Pre-Eclampsia
;
genetics
;
physiopathology
;
Pregnancy
;
Receptors, Androgen
;
genetics
;
physiology
;
Schizophrenia
;
genetics
;
physiopathology
;
Testosterone
;
deficiency
;
Trinucleotide Repeats
10.Evaluation of allelic alterations in 13 CODIS STR loci in tumor tissues from human digestive system.
Jian-xin FANG ; Cheng-tao LI ; Li XIAO
Journal of Forensic Medicine 2007;23(4):280-282
OBJECTIVE:
To study genetic alterations in 13 CODIS STR loci in various tumor tissue samples from human digestive system.
METHODS:
Malignant tumor tissues and blood samples taken from 55 different unrelated individuals were collected. DNA samples were extracted using Chelex100 extraction kit, amplified using Profiler and Cofiler PCR amplification kit and analyzed using API 310 analyzer.
RESULTS:
Aberrant cell divisions were detected in all of the 55 tumor tissue samples, with STR alternations detected in two samples including allelic alteration, partial and complete loss or unbalance of heterozygosity. Moreover, the alternations might occur simultaneously at more than one loci.
CONCLUSION
Caution must be taken in STR analysis of tumor tissue samples since the exclusion loci in forensic identification or paternity testing may be resulted from mutations in the tumor tissue.
Alleles
;
DNA, Neoplasm/analysis*
;
Digestive System Neoplasms/genetics*
;
Gastrointestinal Neoplasms/genetics*
;
Genetic Variation
;
Genotype
;
Humans
;
Loss of Heterozygosity
;
Pancreatic Neoplasms/genetics*
;
Polymerase Chain Reaction
;
Tandem Repeat Sequences/genetics*

Result Analysis
Print
Save
E-mail